UBS Evidence Lab makes available Coronavirus datasets to global media

• Opportunity to access unique data offering usually only available to clients to support real-time reporting and provide a data-based picture of what may be happening during the current global pandemic.
• Accessible alternative data on app usage and downloads, price changes, inventories, transactions, traffic, wait times, availability of seats, hospital admittance and more.
• UBS Evidence Lab has a team of hundreds of global experts from a unique mix of specialisations such as geographers, engineers, hydrologists, epidemiologists, physicists.

London, 19 March 2020– UBS Evidence Lab is unlocking insight-ready Coronavirus (COVID-19) datasets to support our media partners by providing them with information to meet rapid demand for news during the current global pandemic.

For the first time, media will be able to access UBS Evidence Lab’s data on thousands of companies across all regions and sectors. This will help them update their theories more frequently and with a data-based picture of what may be happening during this time of need.

With a team of hundreds of global experts from a unique mix of specialisations such as geographers, engineers, hydrologists, physicists and industry accolades for best in their field, UBS Evidence Lab believes it is well placed to support in this time of need.

UBS is ranked #1 by US Equity Investors 2019 Survey Greenwich Associates for “Best at leveraging alternative data to add value” and UBS Evidence Lab is a key contributor to UBS Research's rise to the top in Global Institutional Investor Equity Research ranking.

For media access to UBS Evidence Lab’s data, please reach out to your local UBS media relations contact for more information.

Sergio P. Ermotti, CEO UBS Group AG, said: “Now more than ever, I believe UBS has a duty to partner with others, beyond our usual stakeholders, to help where ever we can. This is why from today, UBS Evidence Lab, our unique alternative data will now be available to our media partners.”

Barry Hurewitz, Evidence Lab’s head, said: “When an event is as rare as the current COVID-19 pandemic, the use of alternative data is one of the ways left for broader society to figure out what is really happening on the ground. Now more than ever, I believe we collectively need data and analytics to give us an accurate view of what’s really happening in different parts of the world – and this is why UBS Evidence Lab is opening its library of alternative data to the media.”

In addition to accessible datasets on COVID-19, UBS Evidence Lab will host weekly webinar presentations on key themes for press.

About UBS
UBS provides financial advice and solutions to wealthy, institutional and corporate clients worldwide, as well as private clients in Switzerland. UBS' strategy is centered on our leading global wealth management business and our premier universal bank in Switzerland, enhanced by Asset Management and the Investment Bank. The bank focuses on businesses that have a strong competitive position in their targeted markets, are capital efficient, and have an attractive long-term structural growth or profitability outlook.

UBS is present in all major financial centers worldwide. It has offices in 50 markets, with about 31% of its employees working in the Americas, 32% in Switzerland, 19% in the rest of Europe, the Middle East and Africa and 18% in Asia Pacific. UBS Group AG employs over 67,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

About UBS Evidence Lab
UBS Evidence Lab is a sell-side team of experts, independent of UBS Research, that work across 45 specialized labs creating insight-ready datasets. The experts turn data into evidence by applying a combination of tools and techniques to harvest, cleanse, and connect billions of data items each month. The library of assets, covering over 4000+ companies of all sizes, across all sectors and regions, is designed to help investors answer the questions that matter to their investment analysis.

Since 2014, UBS Research Analysts have utilized the expertise of UBS Evidence Lab for insight-ready datasets on companies, sectors, and themes, resulting in the production of over 5,000 differentiated UBS Research reports.
 

UBS Group AG and UBS AG

Disclaimer:
UBS Evidence Lab is a separate business to UBS Research and is not subject to all of the independence disclosure standards applicable to material prepared by UBS Research. UBS Evidence Lab provides data and evidence for analysis and use by UBS Evidence Lab clients including UBS Research; it does not provide research, investment recommendations or advice.

This material is for information only. It is for distribution only under such circumstances as may be permitted by applicable law. It may not be distributed, copied or reproduced without the express prior written consent of UBS. The recipient should not construe the contents of this material as legal, tax, accounting, regulatory, or other specialist or technical advice or services or investment advice or a personal recommendation. Neither UBS nor any of its directors, officers, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material or reliance upon any information contained herein. UBS Evidence Lab is a separate business to UBS Research and is not subject to all of the independence disclosure standards applicable to material prepared by UBS Research. UBS Evidence Lab provides data and evidence for analysis and use by UBS Evidence Lab clients including UBS Research; it does not provide research, investment recommendations or advice.